Tirapazamine

Research use only, not for human use.

Tirapazamine is a potent cytotoxic agent under hypoxic conditions, can induce apoptosis by inducing breaks in single and double-stranded DNA, as well as chromosomal breaks.

Trapazamine, also known as SR-4233,DNA-damaging drug potentially for the treatment of cervical carcinoma, head and neck cancer. Tirapazamine is activated to its toxic form preferentially in the hypoxic areas of solid tumors. Cells in these regions are resistant to killing by radiotherapy and most anticancer drugs. Thus the combination of tirapazamine with conventional anticancer treatments is particularly effective.(In Vitro):Tirapazamine (SR259075) is the optimal drug for combination therapy using Pba.(In Vivo):Tirapazamine (SR259075) (1mg; intravenously injected; twice at a 24-h interval) shows a synergetic effect to kill tumor cells because TPZ was activated under the hypoxic conditions that originated from the PDT with Pba and laser irradiation. .

Tirapazamine (SR259075) is the optimal drug for combination therapy using Pba. Cell Viability Assay Cell Line:SCC7 cells Concentration:1mg Incubation Time:24 h Result:Showed synergism with Pba at ED50, ED90 and ED95.

Tirapazamine (SR259075) (1mg; intravenously injected; twice at a 24-h interval) shows a synergetic effect to kill tumor cells because TPZ was activated under the hypoxic conditions that originated from the PDT with Pba and laser irradiation.. Animal Model:C3H/HeN mice.Dosage:1mg Administration:Tirapazamine (1mg; intravenously injected; twice at a 24-h interval)Result:Suppressed the tumors of mice by using laser irradiation.

Tirapazamine | Tirazone | SR 4233 | SR-4233 | WIN 59075

Others

Other Targets

Others

Cancer

——

27314-97-2

178.15

C7H6N4O2

>98% (HPLC)

DMSO : ≥ 39 mg/m; 218.92 mM

Nc1nn(=O)c2ccccc2n1=O

3-aminobenzo[e][1,2,4]triazine 1,4-dioxide

(-20℃)

With Ice Pack

≥ 2 years